262 related articles for article (PubMed ID: 19417719)
1. Fesoterodine (toviaz) for overactive bladder.
Med Lett Drugs Ther; 2009 May; 51(1311):34-5. PubMed ID: 19417719
[No Abstract] [Full Text] [Related]
2. New drug information: Toviaz.
Physician Assistants' Prescribing Reference
JAAPA; 2009 Jun; 22(6):12. PubMed ID: 19601442
[No Abstract] [Full Text] [Related]
3. The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service.
Warner JL
BJU Int; 2010 Aug; 106(4):586. PubMed ID: 20653664
[No Abstract] [Full Text] [Related]
4. Toviaz approved for overactive bladder.
Traynor K
Am J Health Syst Pharm; 2008 Dec; 65(23):2184. PubMed ID: 19020177
[No Abstract] [Full Text] [Related]
5. Fesoterodine for the treatment of overactive bladder.
Belavic JM
Nurse Pract; 2009 Aug; 34(8):14-5. PubMed ID: 19638887
[No Abstract] [Full Text] [Related]
6. Efficacy and tolerability of fesoterodine in older and younger subjects with overactive bladder.
Kraus SR; Ruiz-Cerdá JL; Martire D; Wang JT; Wagg AS
Urology; 2010 Dec; 76(6):1350-7. PubMed ID: 20974482
[TBL] [Abstract][Full Text] [Related]
7. Re: safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction.
Schaefer W
J Urol; 2006 Nov; 176(5):2311-2; author reply 2312-3. PubMed ID: 17070326
[No Abstract] [Full Text] [Related]
8. Patient-optimized doses of fesoterodine improve bladder symptoms in an open-label, flexible-dose study.
Wyndaele JJ; Goldfischer ER; Morrow JD; Gong J; Tseng LJ; Choo MS
BJU Int; 2011 Feb; 107(4):603-11. PubMed ID: 20860648
[TBL] [Abstract][Full Text] [Related]
9. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
Chapple CR; Van Kerrebroeck PE; Jünemann KP; Wang JT; Brodsky M
BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
[TBL] [Abstract][Full Text] [Related]
10. Early onset of fesoterodine efficacy in subjects with overactive bladder.
Goldman HB; Morrow JD; Gong J; Tseng LJ; Schneider T
BJU Int; 2011 Feb; 107(4):598-602. PubMed ID: 20868387
[TBL] [Abstract][Full Text] [Related]
11. Fesoterodine: a new agent for treating overactive bladder.
Ellsworth P; Berriman SJ; Brodsky M
Am J Manag Care; 2009 Mar; 15(4 Suppl):S115-7. PubMed ID: 19355800
[TBL] [Abstract][Full Text] [Related]
12. New drugs: milnacipran hydrochloride, fesoterodine fumarate, and silodosin.
Hussar DA
J Am Pharm Assoc (2003); 2009; 49(2):347-50. PubMed ID: 19289354
[No Abstract] [Full Text] [Related]
13. Review of fesoterodine.
Vella M; Cardozo L
Expert Opin Drug Saf; 2011 Sep; 10(5):805-8. PubMed ID: 21639817
[TBL] [Abstract][Full Text] [Related]
14. Long-term safety, tolerability and efficacy of fesoterodine treatment in subjects with overactive bladder symptoms.
Van Kerrebroeck PE; Heesakkers J; Berriman S; Padmanabhan Aiyer L; Carlsson M; Guan Z
Int J Clin Pract; 2010 Apr; 64(5):584-93. PubMed ID: 20201992
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological characterization of a novel investigational antimuscarinic drug, fesoterodine, in vitro and in vivo.
Ney P; Pandita RK; Newgreen DT; Breidenbach A; Stöhr T; Andersson KE
BJU Int; 2008 Apr; 101(8):1036-42. PubMed ID: 18279452
[TBL] [Abstract][Full Text] [Related]
16. Durability of treatments for overactive bladder.
Dasgupta P
Int J Clin Pract; 2010 Apr; 64(5):528-9. PubMed ID: 20456203
[No Abstract] [Full Text] [Related]
17. Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome.
Michel MC
Expert Opin Pharmacother; 2008 Jul; 9(10):1787-96. PubMed ID: 18570610
[TBL] [Abstract][Full Text] [Related]
18. FDA approval signals more 'homework' on the horizon in trials.
Waters H
Nat Med; 2011 Jul; 17(7):754. PubMed ID: 21738130
[No Abstract] [Full Text] [Related]
19. Editorial comment on: Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers.
Speakman MJ
Eur Urol; 2009 Sep; 56(3):542-3. PubMed ID: 19070420
[No Abstract] [Full Text] [Related]
20. Editorial comment on: Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers.
Dmochowski R
Eur Urol; 2009 Sep; 56(3):542. PubMed ID: 19070419
[No Abstract] [Full Text] [Related]
[Next] [New Search]
